Exploring an individualised homoeopathic treatment (similimum) to modify anger and reduce blood pressure in patients with mild to moderate essential hypertension

Exploring the role of the homoeopathic similimum in modifying anger: state, trait and expression in patients of mild to moderate essential hypertension.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN26742330

Enrollment

150

Registered

2022-10-18

Start date

2016-01-01

Completion date

Unknown

Last updated

2023-01-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Reduction of anger state, trait and expression in patients with essential hypertension Signs and Symptoms

Interventions

This trial was a randomized, placebo-controlled, comparative, open-label study conducted at an urban and a rural charitable homoeopathic hospital and a plastics factory. The study protocol was conduct

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Suffering from essential hypertension (pre-hypertensives: SBP 120-139 mm Hg, DBP 80-89 mm Hg, stage I hypertensives: SBP 140-159 mm Hg, DBP 90-99 mm Hg; stage II hypertensives: SBP more than or equal to 160 mm Hg, DBP more than or equal to 100 mm Hg 2. Patients on antihypertensive treatment 3. Aged 18-65 years 4. Patients whose history, examination and routine investigations revealed no evidence of apparent secondary cause

Exclusion criteria

Exclusion criteria: 1. Physical examination or routine investigations produced suspicion of a secondary cause for HT 2. Provisional or confirmatory diagnosis of secondary HT 3. Patients with uncontrolled Diabetes Mellitus or any uncontrolled endocrine disorders 4. Patients diagnosed with psychiatric disorders like schizophrenia or endogenous depression 5. Pregnant or breastfeeding mothers having HT

Design outcomes

Primary

Measure	Time frame
1. Anger variables measured using the State-Trait Anger Expression Inventory-2 (STAXI-2) scale at the onset of the study and the end of six months study period: 1.1. State Anger (S-Ang) - the intensity of angry feelings at the time of completion 1.2. Trait anger (T-Ang) - a disposition to experience anger 1.3. Anger Expression-Out (Ax-O) - the expression of angry feelings out 1.4. Anger Expression-In (AX-I) - the suppression of angry feelings 1.5. Anger Control-Out (AC-O) - the prevention of anger expression toward other people or objects 1.6. Anger Control-In (AC-I) - the control of suppressed anger 1.7. Anger Expression Index (AX-index) - overall index of the frequency of anger expression, regardless of direction 2. Systolic and diastolic blood pressure measured using an Omron machine at every follow-up visit at 2-week intervals	—

Measure

Time frame

1. Anger variables measured using the State-Trait Anger Expression Inventory-2 (STAXI-2) scale at the onset of the study and the end of six months study period: 1.1. State Anger (S-Ang) - the intensity of angry feelings at the time of completion 1.2. Trait anger (T-Ang) - a disposition to experience anger 1.3. Anger Expression-Out (Ax-O) - the expression of angry feelings out 1.4. Anger Expression-In (AX-I) - the suppression of angry feelings 1.5. Anger Control-Out (AC-O) - the prevention of anger expression toward other people or objects 1.6. Anger Control-In (AC-I) - the control of suppressed anger 1.7. Anger Expression Index (AX-index) - overall index of the frequency of anger expression, regardless of direction 2. Systolic and diastolic blood pressure measured using an Omron machine at every follow-up visit at 2-week intervals

—

Secondary

Measure	Time frame
There are no secondary outcome measures	—

Countries

India

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026